Optimal blood glucose control and the restoration of physiological insulin secretion is an ongoing medical challenge. Continuous subcutaneous insulin infusion (CSII) aims to restore blood glucose levels and reduce the frequency of hypoglycaemic events. Its benefits include a better glycaemic profile compared with management involving multiple daily insulin injections and giving individuals more flexibility in their everyday lives. The advantages of insulin pumps include basal delivery consistency, adjustable basal rates and low insulin depots. However, experience with CSII indicates that candidates should be selected carefully, be well educated in how use the device and be highly motivated to improve their blood glucose control
Continuous subcutaneous insulin infusion (CSII) for type 2 diabetes mellitus (T2DM) is a promising t...
Use of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes has become inc...
Some identifiable themes for research on con-tinuous subcutaneous insulin infusion (CSII) in the las...
Optimal blood glucose control and the restoration of physiological insulin secretion is an ongoing m...
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Introduction: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Continuous subcutaneous insulin infusion (CSII), more commonly known asinsulin pump therapy, deliver...
Continuous subcutaneous insulin infusion (CSII) is used in selected type1 diabetic subjects to achie...
Continuous subcutaneous insulin infusion (CSII), also known as insulin pump therapy and multiple dos...
Both Continuous Subcutaneous Insulin Infusion (CSI) and Multiple Daily Injections (MDI) are effectiv...
Portable insulin infusion devices are effective and safe insulin delivery systems for managing diabe...
A few people with type 1 diabetes undergo multiple hospital admissions for acute glycaemic events. W...
Continuous subcutaneous insulin infusion (CSII) represents an increasingly popular method of treatin...
Continuous subcutaneous insulin infusion (CSII) represents an increasingly popular method of treatin...
Background: Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre...
Continuous subcutaneous insulin infusion (CSII) for type 2 diabetes mellitus (T2DM) is a promising t...
Use of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes has become inc...
Some identifiable themes for research on con-tinuous subcutaneous insulin infusion (CSII) in the las...
Optimal blood glucose control and the restoration of physiological insulin secretion is an ongoing m...
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Introduction: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Continuous subcutaneous insulin infusion (CSII), more commonly known asinsulin pump therapy, deliver...
Continuous subcutaneous insulin infusion (CSII) is used in selected type1 diabetic subjects to achie...
Continuous subcutaneous insulin infusion (CSII), also known as insulin pump therapy and multiple dos...
Both Continuous Subcutaneous Insulin Infusion (CSI) and Multiple Daily Injections (MDI) are effectiv...
Portable insulin infusion devices are effective and safe insulin delivery systems for managing diabe...
A few people with type 1 diabetes undergo multiple hospital admissions for acute glycaemic events. W...
Continuous subcutaneous insulin infusion (CSII) represents an increasingly popular method of treatin...
Continuous subcutaneous insulin infusion (CSII) represents an increasingly popular method of treatin...
Background: Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre...
Continuous subcutaneous insulin infusion (CSII) for type 2 diabetes mellitus (T2DM) is a promising t...
Use of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes has become inc...
Some identifiable themes for research on con-tinuous subcutaneous insulin infusion (CSII) in the las...